Press Releases

04.25.2024

Pfizer Announces 2024 Shareholder Meeting Preliminary Results

04.24.2024

Pfizer Declares Second-Quarter 2024 Dividend

04.22.2024

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

04.11.2024

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25

04.09.2024

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease

03.20.2024

Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts

03.13.2024

European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease

03.12.2024

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)

03.05.2024

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.29.2024

Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth

02.29.2024

Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults

02.26.2024

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference